Education
About Us
Working with TipRanks
Follow Us
MedCap AB (DE:61MA)
FRANKFURT:61MA
61MA Stock Chart & Stats
€50.30
€0.90(1.70%)
At close: 4:00 PM EST
€50.30
€0.90(1.70%)
Day’s Range― - ―
52-Week Range€29.40 - €59.60
Previous CloseN/A
Volume0.00
Average Volume (3M)4.00
Market Cap
€682.29M
Enterprise Value€7.58B
Total Cash (Recent Filing)€370.40M
Total Debt (Recent Filing)€707.00M
Price to Earnings (P/E)37.4
Beta0.08
Next Earnings
Apr 29, 2026EPS Estimate
0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.45
Shares Outstanding15,077,583
10 Day Avg. Volume0
30 Day Avg. Volume4
Financial Highlights & Ratios
PEG Ratio7.70
Price to Book (P/B)5.67
Price to Sales (P/S)3.90
P/FCF Ratio29.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.12
Revenue Forecast (FY)€209.19M
Bulls Say, Bears Say
Bulls Say
Multi-year Revenue ScalingSustained revenue expansion from ~0.8B to ~2.1B across several years indicates durable top-line momentum driven by subsidiary growth and acquisitions. This scaling supports long-term earnings resilience and provides scope to fund organic investment and tuck-in deals over the next 2–6 months and beyond.
Consistent Operating ProfitabilityMid-teens EBIT margins across the period point to structural operating leverage and margin discipline across its healthcare subsidiaries. Stable profitability supports sustained internal cash generation, reinvestment capacity, and the ability to withstand cyclical pressures in healthcare procurement and budgets over multiple quarters.
Positive Free Cash Flow Track RecordConsistent, growing free cash flow provides a durable funding source for dividend upstreaming, capex, and acquisitions central to MedCap's buy-and-build model. Positive FCF reduces reliance on external financing and underpins the group's capacity to invest in portfolio companies over the medium term.
Bears Say
Rising LeverageA marked step-up in debt and higher debt-to-equity reduces balance-sheet flexibility and increases interest and refinancing risk. For an acquisitive holding company, higher leverage constrains ability to pursue new deals or absorb shocks and may pressure credit metrics over the coming quarters.
Uneven Cash ConversionInconsistent conversion of earnings into operating cash (OCF below reported earnings in multiple years) signals working-capital volatility or timing issues. This weakens the reliability of internal cash for dividends, debt service, and acquisitions and raises the need for vigilant liquidity management in the near term.
Gross-margin VolatilityA sharp gross-margin decline suggests mix shifts, pricing pressure, or rising input costs at the subsidiary level. Margin swings threaten sustained operating profitability and complicate forecasting and integration plans for acquired businesses, making near-term margin recovery a structural priority.
MedCap AB News
61MA FAQ
What was MedCap AB’s price range in the past 12 months?
MedCap AB lowest stock price was €29.40 and its highest was €59.60 in the past 12 months.
What is MedCap AB’s market cap?
MedCap AB’s market cap is €682.29M.
When is MedCap AB’s upcoming earnings report date?
MedCap AB’s upcoming earnings report date is Apr 29, 2026 which is in 48 days.
How were MedCap AB’s earnings last quarter?
MedCap AB released its earnings results on Feb 06, 2026. The company reported €0.454 earnings per share for the quarter, beating the consensus estimate of €0.446 by €0.008.
Is MedCap AB overvalued?
According to Wall Street analysts MedCap AB’s price is currently Overvalued.
Does MedCap AB pay dividends?
MedCap AB does not currently pay dividends.
What is MedCap AB’s EPS estimate?
MedCap AB’s EPS estimate is 0.44.
How many shares outstanding does MedCap AB have?
MedCap AB has 15,077,583 shares outstanding.
What happened to MedCap AB’s price movement after its last earnings report?
MedCap AB reported an EPS of €0.454 in its last earnings report, beating expectations of €0.446. Following the earnings report the stock price went up 8.994%.
Which hedge fund is a major shareholder of MedCap AB?
Currently, no hedge funds are holding shares in DE:61MA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MedCap AB
MedCap AB (publ) is a private equity firm specializing in investments in secondary direct, later stage, industry consolidation, growth capital, middle market, mature, turnarounds, buyout. It prefers to invest in healthcare equipment and services, biotechnology, life sciences, and pharmaceuticals companies. The firm prefers to invest in small to medium size companies that are not listed on the stock exchange and are based in Northern Europe. It typically invests between SEK25 million ($2.75 million) to SEK150 million ($16.51 million) with enterprise value and sales revenue between SEK50 million ($5.90 million) to SEK200 million ($23.06 million) and EBITDA between SEK1 million ($0.11 million) to SEK50 million ($5.50 million). The firm seeks to acquire stakes between 20% and 50% in its portfolio companies. It uses its capital and loans and makes balance sheet investments. MedCap AB (publ) was founded in 2001 and is based in Stockholm, Sweden.
Technical Analysis
Options Prices
Currently, No data available
---